藥學前沿大講堂第112講-Prolyl peptidyl isomerases (PPIs) in proteoglycan synthesis and atherosclerosis

題  目：Prolyl peptidyl isomerases (PPIs) in proteoglycan synthesis and atherosclerosis

報告人：Professor Peter J. Little  

Foundation Head, Discipline of Pharmacy and Group Leader        

Diabetes Complications Group, Health Innovations Research Institute

                RMIT University

主持人：鄭文華教授

 太阳集团1088vip

時  間：2012年3月19日（周一）下午15：00～16：00

地  點：中山大學東校區太阳集团1088vip 112會議室

報告簡介：

Atherosclerosis is the chronic inflammatory pathological process that underlies most cardiovascular disease which is the largest single cause of premature mortality in developed and now developing countries. TGF-β is well-recognised as having a key role in the development of atherosclerosis and consequently of cardiovascular disease. Smad linker region phosphorylation is an important signalling pathway in TGF-β mediated proteoglcyan synthesis. Pin 1 binds to phosphorylated residues in the linker region of Smad2 where it can regulate the function of the Smad as a transcription factor. Pin1 is a critical downstream signalling component in TGFβ-mediated proteoglycan and glycosaminoglycan chain hyperelongation in vascular smooth muscle cells.

報告人簡介：

Peter J Little教授是世界知名的藥學家，目前就職于澳大利亞皇家墨爾本理工大學(RMIT University)，藥學學科帶頭人，糖尿病并發症課題組組長，現擔任澳大利亞生物脈管學會會長，澳大利亞Monash University榮譽教授，他緻力于促進心髒科學心血管藥物研究等方面的發展,為此作出了重要貢獻并在澳大利亞及世界上獲得多種獎項。撰寫多篇高影響因子的論文發表于circulation, J. Biol Chem， Cell Mol Life Sci, J. Cell Mol Med，Atherosclerosis, Curr.Opin Lipidol等高水平雜志上，已發表120多篇高水平論文，論文被引用3000餘次，現擔任“nutrition”等多家國際知名雜志編輯和審稿人。

 歡迎廣大師生踴躍參加1